Showing 5241-5250 of 5799 results for "".
- L'Oreal International Extends Deadline for Social Responsibility in Dermatology Awardshttps://practicaldermatology.com/news/loreal-international-extends-deadline-for-social-responsibility-in-dermatology-awards/2458996/L’Oréal announced today the extension of the closing date of its International Awards for Social Responsibility in Dermatology to April 15th 2015. Patients with dermatological conditions may frequently face discrimination and feel socially excluded,
- Promius Pharma, LLC to Market, Distribute Trianex 0.05%https://practicaldermatology.com/news/promius-pharma-llc-to-market-distribute-trianex-005/2458997/Promius Pharma, LLC, has acquired the rights to market and distribute Trianex® 0.05% (Triamcinolone Acetonide Ointment, USP) in the United States from CMP Pharma, Inc. Trianex Ointment, a mid-potency corticosteroid, is notable for its white formulation that has the look and feel of
- POWER Study Suggests EpiDuo plus Doxycycline May be an Alternative to Isotretinoinhttps://practicaldermatology.com/news/power-study-suggests-epiduo-plus-doxycycline-may-be-an-alternative-to-isotretinoin/2459000/Doxycycline 200 mg plus adapalene 0.1%/benzoyl peroxide 2.5% gel (D+A/BPO) is an alternative to isotretinoin in patients intolerant to, or unable or unwilling to take, oral isotretinoin, and is an option for treatment of severe nodular acne, according to a new study. Findings suggest that th
- Investigational Atopic Dermatitis Cream Disappoints in Phase II Trialhttps://practicaldermatology.com/news/investigational-atopic-dermatitis-cream-disappoints-in-phase-ii-trial/2459003/Results from a phase II trial do not bode well for the future of the investigational atopic dermatitis cream MRX-6. The double-blind, parallel-group, vehicle-controlled study evaluated the safety and efficacy of MRX-6 cream 2% among 73 children suffering from mild-to-moderate atopic dermatitis. P
- derma e® Introduces Scalp Relief Hair Carehttps://practicaldermatology.com/news/derma-e-introduces-scalp-relief-hair-care/2459006/derma e® launched its new Scalp Relief Shampoo and Conditioner. derma e® Scalp Relief Shampoo and Scalp Relief Conditioner work in four therapeutic ways to effectively target scalp problems. The shampoo is designed to cleanse, de-flake, soothe and nourish. The conditioner is designed to d
- New App for Clinical Skin Cancer Diagnosis Launches on World Cancer Day 2015; Physician Input Soughthttps://practicaldermatology.com/news/new-app-for-clinical-skin-cancer-diagnosis-launches-on-world-cancer-day-2015-physician-input-sought/2459012/On World Cancer Day 2015, general practitioners, physicians, and dermatologists in the United States, United Kingdom and Australia were asked for their feedback during the advanced trial phase of a new, free app that has the potential to play a role in the clinical detection of skin cancer.
- Lumenis Expands Product Line with a New ResurFX Systemhttps://practicaldermatology.com/news/lumenis-expands-product-line-with-a-new-resurfx-system/2459013/Lumenis Ltd. launched its new ResurFX™ laser system for fractional non-ablative skin resurfacting treatments. This new ResurFX system is a stand-alone desktop solution, which builds upon the successful launch of ResurFX module for the M22™ multi-application platform. The system d
- Galderma Launches Restylane Silk for Lip Enhancement and Treatment of Perioral Lineshttps://practicaldermatology.com/news/galderma-launches-restylane-silk-for-lip-enhancement-and-treatment-of-perioral-lines/2459015/Galderma launched Restylane® Silk, the first and only dermal filler FDA approved for lip enhancement and the treatment of wrinkles and lines around the mouth in people over the age of 21. Restylane Silk is a smooth gel designed to restore natural youthful definitio
- Alphaeon Begins Phase III Study For Its Neurotoxin, Evosyalhttps://practicaldermatology.com/news/alphaeon-begins-phase-iii-study-for-its-neurotoxin-evosyal/2459018/The FDA agreed to Alphaeon® Corporations’s protocol for its Phase III clinical study of Evosyal™ to treat glabellar lines. Alphaeon acquired the exclusive US and certain international distribution rights to Evosyal, a botulinum toxin type A neuromodulator, as part of it
- Dr. Zein Obagi's New Book Presents the Art and Science of Skin Healthhttps://practicaldermatology.com/news/dr-zein-obagis-new-book-present-the-art-and-science-of-skin-health/2459023/Zein Obagi, MD, founder of ZO Skin Health, Inc., has published a new book, The Art of Skin Health Restoration and Rejuvenation: The Science of Clinical Practice, Second Edition (CRC Press, Dec 2014). In it, he reveals the Zein Ob